Psoriasis

Lancet

Volumn 361, Issue 9364, 2003, Pages 1197-1204

  Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ANTIPSORIASIS AGENT; CALCIPOTRIOL; CALCITRIOL; CORTICOSTEROID; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; DENILEUKIN DIFTITOX; DITHRANOL; EFALIZUMAB; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; ETRETIN; GALIXIMAB; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY ABX INTERLEUKIN 8; PIMECROLIMUS; RETINOID; SALICYLIC ACID; SIPLIZUMAB; TACALCITOL; TAR; TAZAROTENE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

APHTHOUS STOMATITIS; ARTERY THROMBOSIS; BLOOD CLOTTING DISORDER; BONE MARROW TOXICITY; CELL PROLIFERATION; CHEILITIS; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE RELEASE; DRUG SAFETY; DRUG TARGETING; FEVER; GENETIC ASSOCIATION; HAIR LOSS; HEADACHE; HUMAN; KERATINOCYTE; LIVER FIBROSIS; MYALGIA; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; SIDE EFFECT; SKIN ATROPHY; SKIN IRRITATION; STRIA; T LYMPHOCYTE ACTIVATION; TACHYPHYLAXIS; TELANGIECTASIA; TOPICAL TREATMENT; VASOSPASM; VOMITING;

EID: 0037420518     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12954-6     Document Type: Conference Paper

References (99)

1. Green M.S., Prystowsky J.H., Cohen S.R., Cohen J.I., Lebwohl M.G. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol. 34:1996;911-914.
2. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 14:1996;485-496.
3. Biondi Oriente C., Scarpa R., Pucino A., Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Dermatol Venereol. 146:(suppl):1989;69-71.
4. Tham S.N., Lim J.J., Tay S.H., et al. Clinical observations on nail changes in psoriasis. Ann Acad Med Singapore. 17:1988;482-485.
5. Gladman D.D., Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs. 9:2000;1511-1522.
6. Scarpa R., Oriente P., Pucino A., et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol. 23:1984;246-250.
7. Poikolainen K., Karvonen J., Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol. 135:1999;1490-1493.
8. Gladman D.D., Farewell V.T., Wong K., Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 41:1998;1103-1110.
9. Shbeeb M., Uramoto K.M., Gibson L.E., O'Fallon W.M., Gabriel S.E. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 27:2000;1247-1250.
10. Margolis D., Bilker W., Hennessy S., et al. The risk of malignancy associated with psoriasis. Arch Dermatol. 137:2001;778-783.
11. Stern R.S. Psoriasis. Lancet. 350:1997;349-353.
12. Menter A., Barker J.N. Psoriasis in practice. Lancet. 338:1991;231-234.
13. Barker J.N. The pathophysiology of psoriasis. Lancet. 338:1991;227-230.
14. Duffy D.L., Spelman L.S., Martin N.G. Psoriasis in Australian twins. J Am Acad Dermatol. 29:1993;428-434.
15. Brandrup F., Holm N., Grunnet N., Henningsen K., Hansen H.E. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Dermatol Venereol. 62:1982;229-236.
16. Barker J.N. Genetic aspects of psoriasis. Clin Exp Dermatol. 26:2001;321-325.
17. Capon F., Munro M., Barker J., Trembath R. Searching for the major histo-compatibility complex psoriasis susceptibility gene. J Invest Derm. 118:2002;745-751.
18. Asumalahti K., Veal C., Laitinen T., et al. Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum Mol Genet. 11:2002;580-597.
19. Allen M., Ishida-Yamamoto A., McGrath J., et al. Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders. Lab Invest. 81:2001;969-976.
20. Bjerke J.R., Krogh H.K., Matre R. Characterization of mononuclear cell infiltrates in psoriatic lesions. J Invest Derm. 71:1978;340-343.
21. Krogh H.K., Bjerke R. Identification of subpopulation of mononuclear cells in psoriatic lesions. Acta Dermatol Venereol. 21:1979;87.
22. Snowden J.A., Heaton D.C. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive auto-immunity. Br J Dermatol. 137:1997;130-132.
23. Gottlieb S.L., Gilleaudeau P., Johnson R., et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1:1995;442-447.
24. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 46:2002;1-23.
25. Singri P., West D.P., Gordon K.B. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Derm. 138:2002;657-663.
26. Goeckerman W.H. Treatment of psoriasis. Northwest Med. 24:1925;15229.
27. Jones S.K., Campbell W.C., Mackie R.M. Out-patient treatment of psoriasis: short contact and overnight dithranol therapy compared. Br J Dermatol. 113:1985;331-337.
28. Volden G., Bjornberg A., Tegner E., et al. Short-contact treatment at home with Micanol. Acta Dermatol Venereol. 172:1992;20-22.
29. Nagpal S., Lu J., Boehm M.F. Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem. 8:2001;1661-1679.
30. Lebwohl M., Ast E., Callen J.P., et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 38:1998;705-711.
31. Abels D.J., Harari M. Psoriasis remission time at the Dead Sea. J Am Acad Dermatol. 43:2000;325-326.
32. Larko O. Treatment of psoriasis with a new UVB-lamp. Acta Dermatol Venereol. 69:1989;357-359.
33. Coven T.R., Burack L.H., Gilleaudeau R., Keogh M., Ozawa M., Krueger J.G. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broad-band UV-B. Arch Dermatol. 133:1997;1514-1522.
34. Melski J.W., Tanenbaum L., Parrish J.A., Fitzpatrick T.B., Bleich H.L. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol. 68:1977;328-335.
35. Stern R.S., Liebman E.J., Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer: PUVA Follow-up Study. J Natl Cancer Inst. 90:1998;1278-1284.
36. Stern R.S., Nichols K.T., Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen)and ultraviolet A radiation (PUVA): the PUVA Follow-Up Study. N Engl J Med. 336:1997;1041-1045.
37. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol. 28:1993;466-469.
38. Roenigk H.H. Jr, Auerbach R., Maibach H., Weinstein G., Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 38:1998;478-485.
39. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol. 41:(suppl):1999;S22-S24.
40. Zachariae H., Kragballe K., Hansen H.E., Marcussen N., Olsen S. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol. 136:1997;531-535.
41. Schopf R.E. Pimecrolimus. Novartis. Curr Opin Investig Drugs. 3:2002;720-724.
42. Rappersberger K., Komar M., Ebelin M.E., et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis, and is well tolerated. J Invest Dermatol. 119:2002;876-887.
43. Martin A., Gutierrez E., Muglia J., et al. A multicenter dose-escalation trial with denileukin diftitox (ONTAK,DAB (389)IL-2) in patients with severe psoriasis. J Am Acad Dermatol. 45:2001;871-881.
44. Lohner M.E., Krueger J.G., Gottlieb A., et al. Clinical trials of a fully human anti-IL-8 antibody for the treatment of psoriasis. Br J Dermatol. 141:1999;989.
45. Gottlieb A., Abdulghani A., Totoritis R., et al. Results of a single-dose, dose escalating trial of an anti-B7 monoclonal antibody (IDEC-114) in patients with psoriasis. J Invest Dermatol. 114:2000;840.
46. Abrams J.R., Lebwohl M.G., Guzzo C.A., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 103:1999;1243-1252.
47. Langley R., Roenigk H.H., McCall C., Stricklin G., Dingivan C. Phase I results of intravenous MEDI-507, an anti-T-cell monoclonal antibody, for the treatment of psoriasis. J Invest Dermatol. 117:2001;817.
48. Krueger J.G., Walters I.B., Miyazawa M., et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol. 43:2000;448-458.
49. Asadullah K., Sterry W., Stephanek K., et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest. 101:1998;783-794.
50. Friedrich M., Docke W.D., Klein A., et al. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J Invest Dermatol. 118:2002;672-677.
51. The Research Pipeline for Psoriasis. The Bulletin. 31:2000;8-9.
52. Schopf R.E., Hocher J., Rehder M., Farber L., Morsches B. Etretinate or cyclosporin-A treatment normalises the enhanced respiratory burst of polymorphonuclear leukocytes in psoriasis. Arch Dermatol Res. 284:1992;227-231.
53. Tanew A., Radakovic-Fijan S., Schemper M., Honigsmann H. Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: a paired comparison study. Arch Dermatol. 135:1999;519.
54. Ring J., Kowalzick L., Christophers E., et al. Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol. 144:2001;495-499.
55. Callis K.P., Chadha A., Vaishnaw A.K., Krueger G.G. Reductions of CD45RO+ effector T lymphocytes is not observed in the treatment of psoriasis with methotrexate. J Investig Derm. 119:2002;244.
56. Tan M.H., Gordon M., Lebwohl O., George J., Lebwohl M.G. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 137:2001;930-933.
57. Oh C.J., Das K.M., Gottlieb A.B. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 42:2000;829-830.
58. Chaudhari U., Romano P., Mulcahy L.D., et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 357:2001;1842-1847.
59. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1998;1552-1563.
60. Remicade. P. Product information: physicians' desk reference. 2002;1181 Medical Economics Company, Montvale, NJ.
61. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 345:2001;1098-1104.
62. Aithal G.P., Mansfield J.C. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharm Ther. 15:2001;1101-1108.
63. Cohen R.B., Dittrich K.A. Anti-TNF therapy and malignancy: a critical review. Can J Gastroenterol. 15:2001;376-384.
64. Ogilvie A.L., Antoni C., Dechant C., et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 144:2001;587-589.
65. Martinez F., Nos P., Benlloch S., Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis. 7:2001;323-326.
66. Kobbe G., Schneider P., Rohr U., et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNF alpha antibody. Bone Marrow Transplant. 28:2001;47-49.
67. Voigtlander C., Luftl M., Schuler G., Hertl M. Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol. 137:2001;1571-1574.
68. Steinfeld S.D., Demols P., Salmon I., Kiss R., Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum. 44:2001;2371-2375.
69. Goossens P.H., Verburg R.J., Breedveld F.C. Remission of Behcet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis. 60:2001;637.
70. Brandt J., Haibel H., Cornely D., et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 43:2000;1346-1352.
71. Cantini F., Niccoli L., Salvarani C., Padula A., Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 44:2001;2933-2935.
72. Chey W.Y., Hussain A., Ryan C., Potter G.D., Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol. 96:2001;2373-2381.
73. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 356:2000;385-390.
74. Gottlieb A.B., Matheson R.T., Lowe N.J., Zitnik R.J. Efficacy of etanercept in patients with psoriasis. J Invest Dermatol. 119:2002;234.
75. Nuijten M.J., Engelfriet P., Duijn K., Bruijn G., Wierz D., Koopmanschap M. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics. 19:2001;1051-1064.
76. Enbrel. Etanercept package insert. Sifton D., Westley G., Mazur J., Woemer R. Physician's desk reference. 2002;Medical Economics Company, Montvale, NJ.
77. Shakoor N., Michalska M., Harris C.A., Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 359:2002;579-580.
78. Bleumink G.S., ter Borg E.J., Ramselaar C.G., Ch Stricker B.H. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology. 40:2001;1317-1319.
79. Ferraccioli G., Mecchia F., Di Poi E., Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis. 61:2002;358-361.
80. Moreland L.W., Schiff M.H., Baumgartner S.W., et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med. 130:1999;478-486.
81. Mohan N., Edwards E.T., Cupps T.R., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 44:2001;2862-2869.
82. Sacher C., Rubbert A., Konig C., Scharffetter-Kochanek K., Krieg T., Hunzelmann N. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Derm. 46:2002;113-115.
83. Henter J.I., Karlen J., Calming U., ernstrand C., Andersson U., Fadeel B. Successful treatment of Lanagerhans'-cell histiocytosis with etanercept. N Engl J Med. 345:2001;1577-1578.
84. Stone J.H., Uhlfelder M.L., Hellmann D.B., Crook S. Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 44:2001;1149-1154.
85. Barthel H.R. Rapid remission of treatment-resistant ankylosing spondylitis with etanercept: a drug for refractory ankylosing spondylitis? Arthritis Rheum. 45:2001;404.
86. Takei S., Groh D., Bernstein B., Shaham B., Gallagher K., Reiff A. Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J Rheumatol. 28:2001;1677-1680.
87. Ellis C.N., Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 345:2001;248-255.
88. Gottlieb AB, Vaishnaw A, Gordon K. Immune response to neo- recalled antigens is not altered by alefacept. 60th Annual Meeting of the American Academy of Dermatology. New Orleans, LA; February, 2002.
89. Lowe N, Krueger GG, Menter A, Vigliani G, O'Gorman J, Ellis C. Results of interim analyses of repeat courses of intramuscular alefacept therapy for the treatment of chronic plaque psoriasis. 60th Annual Meeting of the American Academy of Dermatology. New Orleans, LA; February, 2002. 60th Annual meeting of the American Academy of Dermatology. New Orleans, LA; February, 2002.
90. Lebwohl M, Bissonnette R, Ellis C, et al. Results of a multiple-course, randomized phase III study of alefacept in patients with chronic plaque psoriasis. 60th Annual meeting of the American Academy of Dermatology. New Orleans, LA; February, 2002.
91. Krueger GG, Rizova E. Duration of response to alefacept therapy in patients with chronic plaque psoriasis. 60th Annual meeting of the American Academy of Dermatology. New Orleans, LA; February, 2002.
92. Gottlieb A. Efalizumab (anti-CD11A) induction and maintenance treatment during a 12-month trial in patients with moderate to severe plaque psoriasis: preliminary findings. 60th Annual meeting of the American Academy of Dermatology. New Orleans, LA; February, 2002.
93. Koo JY. Efalizumab (anti-CD11a) is safe and well tolerated in the treatment of moderate to severe plaque psoriasis: pooled results of two phase III clinical trials. 60th Annual meeting of the American Academy of Dermatology. New Orleans, LA; February, 2002.
94. Gottlieb A.B., Krueger J.G., Wittkowski K., Dedrick R., Walicke P.A., Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol. 138:2002;591-600.
95. Leonardi C. Efalizumab (anti-CD11a): promising results when used for the treatment of moderate to severe plaque psoriasis. 60th Annual meeting of the American Academy of Dermatology. New Orleans, LA; February, 2002.
96. Menter A. Time to onset of improvement during efalizumab (anti-CD11a) therapy in patients with moderate to severe plaque psoriasis. 60th Annual meeting of the American Academy of Dermatology. New Orleans, LA; February, 2002.
97. Lebwohl M. Continued treatment with efalizumab (anti-CD11A) improves outcome in patients with moderate to severe plaque psoriasis. 60th Annual meeting of the American Academy of Dermatology. New Orleans, LA; February, 2002.
98. Bhushan M., Bleiker T.O., Ballsdon A.E., et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol. 146:2002;824-831.
99. Bagel J., Garland W.T., Breneman D., et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol. 38:1998;938-944.